Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs

NCT04915144 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT04915144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04915144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Withdrawn
Start date
January 15, 2023
Completion date
December 31, 2031
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumor, gastrinoma, gastroenteropancreatic neuroendocrine tumor, insulinoma, neuroendocrine tumors, pulmonary carcinoid tumor, vipoma